univers coverag
calendar event
investor tour visit heart healthcar facil bu tour
investor tour visit heart healthcar facil bu tour
pleas refer disclosur appendix analyst certif import disclosur price chart
disclosur specif cover compani avail
contact leerink partner editori depart statement valuat risk avail note
follow public contact leerink partner editori depart rx trend deriv im
regulatori event gener restasi bridg goal date chronic dri eye see note
medic meet american associ clinic chemistri american associ
physicist medicin
pamrevlumab pancreat cancer develop like slower riskier pt
bottom line fibrogen two-product compani note revisit outlook
compani second wholli own clinic program pamrevlumab pamrevlumab
compani anti-ctgf antibodi develop varieti indic involv fibrot
infiltr two advanc indic idiopath pulmonari fibrosi ipf local
advanc pancreat cancer lapc new data present pancreat cancer earlier year
result compani develop plan disclos examin
feasibl compani propos acceler develop plan local advanc pancreat
cancer discuss lead pancreat cancer specialist suggest investor
expect type acceler file indic despit high unmet need research
suggest compani need complet anoth much larger trial pivot proceed
indic probabl need show improv overal surviv part trial rather
compani previous propos surgic resect endpoint compani studi thu far
size durat trial like larger longer previous anticip
reason push timelin approv pamrevlumab indic
model although remain posit stock alter time
effect lower target price still expect stock driven
manag discuss develop plan ipf emerg safeti efficaci
result roxadustat anemia indic
pamrevlumab data lapc impress closer examin
substanti develop risk still remain lapc indic
approv lapc could anoth year away
leerink pamrevlumab revenu forecast lapc push lapc
new nation kaiser ascens medicar advantag
bottom line mp ascens health largest cathol nonprofit health system
countri announc letter intent loi explor creation joint ventur
medicar advantag plan serv multipl market view posit
manag follow recent commentari acceler growth larg
grow lucr market strategi offer window potenti futur vertic combin
among payor provid seek combin underwrit rx benefit popul
health manag capabl provid network health system support recent
acquisit cathol health plan fide expect serv medicar beneficiari
 revenu exposur end across state notabl ascens
presenc state togeth penetr rate joint ventur
well posit combat typic payor-provid challeng gop polici drive
tailwind underwrit technolog expertis combin ascens provid
network clinic capabl could time creat signific integr payer/provid entiti
previous unseen outsid kaiser pleas see follow link review link
ascens headquart st loui signific geograph overlap
overal announc joint ventur loi explor creation plan
increasingli battleground rate tax polici trump administr like
foster penetr
signal posit commit futur driver growth confirm earlier manag
commentari leverag complementari expertis overlap footprint
joint ventur dovetail ascens health strategi geograph footprint well leverag
local domin
partnership immun associ risk
ali fda-land optimist po adcom refractori ntm
discount rate termin growth rate
bottom line base vote histori past antimicrobi drug advisori committe adcom
member expect ye vote vote amikacin liposom inhal suspens
ali august although like wont landslid assess safeti efficaci data
ali current treatment paradigm nontubercul mycobacterial/ntm lung diseas caus
mycobacterium avium complex/mac suggest overal potenti posit vote base
unmet medic need among refractori pt ntm lung diseas caus improv safeti
profil ali inhal amikacin inject amikacin use harder treat pt
efficaci demonstr meet program primari endpoint cultur convers
panel focu safeti efficaci ali page believ in-depth
dialogu could whether broader label warrant although dont expect one remain posit
outcom outlin five key consider within preview reiter outperform rate
ali look safe modest dropout rate
target appropri ntm subgroup
ali data garner favor review panel
durabl minut walk distanc could major discuss point
believ like label recommend second-lin treatment refractori ntm
pt caus finit period time
move forward ex-u mainten therapi
in-lin guidanc lower fx interest uk ss rev cont
bottom line report rel in-lin quarter across revenu ebitda ep
guidanc lower due deterior exchang rate increas interest
expens uk segment rebound continu ss revenu trend beat expect
acceler qoq yoy admiss price trend ahead expect patient day
lo miss view continu convert uk bed match demand us segment
ss revenu trend miss expect deceler yoy qoq admiss price
beat expect opex rel line suppli opex beat swb
miss bp remain activ ad bed us uk expect call
tuesday et focu fundament bh facil busi updat
improv uk segment chang referr local govern vs nh
staf pressur well fundament us busi
rel line revenu ebitda ep
guidanc lower due fx expect increas interest expens
uk segment fundament continu rebound ss revenu grow expect trend
improv bp qoq bp yoy
us segment ss revenu trend miss expect deceler qoq yoy admiss
price beat expect
consolid oper expens rel line
manag host confer call tuesday juli et dial-in detail
passcod need
solid result revenu earn ahead model book
provid add collect rate ahead expect book declin
y/i perform quarter far better y/i declin experienc
manag narrow revenu guid midpoint adjust oper incom
guidanc increas slightli manag highlight review strateg altern
includ possibl sale busi merger remain independ sound
sale forc right-siz cost-reduct effort bear fruit given solid
beat cost control decent book increas revenu ep
estim given offer price elliott maintain mp rate pt
result athn continu show good oper leverag
guidanc narrow adj op adj om guidanc increas
book declin y/i stabl
network growth continu crack emerg
strateg altern process underway estim deal highli like
bottom line market close report sale us
y/i consensu also guid top-lin
-- exceed consensu line us y/i midpoint
guidanc confirm recent view taken appropri measur --
addit rhonda robb head sale restructur sale force/ad clinic
sale specialist execut strateg partnership order expand product offer --
realiz compani full growth potenti peg solidli double-digit rang overal
believ investor view result just-issu guidanc posit
importantli expect bullish long-term guidanc analyst meet tomorrow stock
react accordingli continu believ repres sustain mid-teen growth stori
-- least -- next year given believ compani signific competit
advantag calcifi below-the-kne lesion within peripher well grow
market-lead posit highli under-penetrated coronari market
analyst day tomorrow like detail lt growth potenti exist busi supplement
first-ev look pipelin
elast demand drive consum growth pt
bottom line remain op believ lower sequenc cost competit
among custom continu drive novaseq product upgrad cycl year
launch deliv anoth strong quarter driven except strong consum
pickup broadli across custom base research clinic set believ
increasingli becom consum stori longer term novaseq provid path genom
make flowcel upgrad far frequent instrument launch everi flowcel launch
cost per gb come drive increas sequenc volum expect drive overal
consum higher wake updat reiter outperform rate move price
target
novaseq elast demand continu deliv
consum genom demand drove growth quarter
guidanc rais may still conserv
edico genom like get incorpor novaseq box
half full half empti alzheim diseas puls call takeaway
averag dcf price-to-earnings p/sale
texa re-issu star plu rfp opportun knock mco
 methodolog averag dcf price-to-earnings p/sale
pro-forma ebitda leverag
dcf analysi revenu multipl dr tgr
pt
 methodolog ep
retir
earn deal backlog still flat sequenti
slowli sure sight acceler improv pt
 methodolog cash ep
aug aug orkambi kalydeo cystic fibrosi fda approv
thesi base continu captur cystic fibrosi cf patient subpopul
vertex success iter cf modul oral combin medicin
multipl near term catalyst approach link
august fda approv orkambi treat cystic fibrosi cf children
year age expect
august look fda approv kalydeco treat cf infant
month age
later anticip multipl develop includ
phase result kalydeco cf infant month age
ema approv symdeko treatment homozyg patient
phase result symdeko cf children age year old
eu approv orkambi treat homozyg patient year age
also expect initi phase i/ii trial treatment beta thalassemia
europ sickl cell diseas respect
believ investor expect head ph data readout
low especi sinc lack clariti around requir approv
still discuss fda around data analysi plan studi
niemann-pick type np-c ultra-rar progress neurodegen genet
diseas occur bodi properli break cholesterol lipid
lead harm amount lipid accumul spleen liver brain
believ ph i/ii result encourag given breakthrough
statu drug fda prior comment bar approv like low
medacorp specialist spoke enthusiast current
treatment altern off-label use miglustat limit efficaci high ae
rate diarrhea abdomin pain nausea
forecast sale grow larg opportun
believ one sever pipelin asset critic offset
declin key franchis acthar inomax ofirmev face competit
come year posit regulatori execut increas investor
interest emerg pipelin
one regn import catalyst approv antibodi cemiplimab
cutan squamou cell carcinoma cscc
compani pdufa date octob research suggest first approv
checkpoint antibodi new indic typic come ahead pdufa date like
june juli cemiplimab estim
particularli true applic benefit breakthrough design
prioriti review case cemiplimab
regeneron also appear signal expect approv occur earlier
date confirm us commerci team readi launch product
immedi avail channel
project peak pos-adjust us cemiplimab sale
aug omadacyclin antibiot skin pneumonia adcom
key catalyst remain time-frame conven adcom aug
potenti approv oct time-frame could move stock meaning
view fda decis panel indic concern
link view panel public forum review posit risk/
benefit profil omadacyclin evidenc last nce antibiot pneumonia
sinc adcom conven
continu view data packag omadacyclin support approv
believ current level street underappreci valu omadacyclin
gain clariti key discuss topic brief document
releas publicli two busi day ahead adcom date
pdufa date expect octob
mid-august hire extern sale rep cologuard screen
cologuard highli under-penetr strong popul need
colorect cancer screen believ could deliv penetr
revenu longer term penetr ttm sale
recent analysi util leerink healthcar advanc analyt suggest
hire extern rep remain track complet mid-august earlier
timelin highlight
view revenu growth depend fast compani hire sale rep
particularli extern rep harder find hire intern one
turn drive new physician reorder catalyz growth exist physician order
rep hire faster abl reach new pcp aggress
abl serv exist account sooner and/or frequent -- ultim drive upsid
estim take month rep becom fulli product
result updat like earli august
call announc earlier-than-expect complet enrol
follow-up stemi short-term elev myocardi infarct feasibl studi
put data present like aha chicago pivot trial start
possibl earli time-frame sooner base estim
esposito et al publish result anim studi jacc support left
ventricular unload prior reperfus translat human would impli impella
success stemi reduc infarct size prevent late-stag onset
heart failur -- someth would clinic relev also cost effect
concurr editori jacc review clearli bullish implic
esposito studi potenti impella use stemi patient outcom
reproduc human primari mechan lv unload enorm benefit
reduc futur hf event patient acut mi note intervent cardiologist
may also need prepar modifi therapeut strategi mi
estim stemi year would
doubl exist address patient popul high risk pci cardiogen
believ data present american psychiatr associ confer
provid limit insight genesight endpoint
view test key mygn long-term top-lin growth potenti
drive revenu upsid reimburs mygn desir
current medicar rate
signific controversi alreadi surround reach potenti given
pt trial fail meet primari endpoint met secondari endpoint remiss
respons data may provid sub-
analysi patient fail chang view medacorp specialist payer
journal public expect june coverage/contract decis expect
announc beyond
link takeaway meet manag
regulatori settlement behavior health feder state agenc appear like
posit catalyst
negoti remain on-going manag optimist settlement reach
investig state feder regul year
settlement reserv increas pre-tax
sourc leerink research compani inform factset price prior day
gener restasi bridg goal date chronic dri eye see note
fda adcom joint meet drug safeti risk manag anesthet
fda adcom antimicrobi drug omadacyclin acut bacteri skin skin
structur infect absssi community-acquir bacteri pneumonia cabp
medcac panel t-cell therapi
fda public hear biosimilar silver spring md
pdufa teva fremanezumab cgrp migrain
fda adcom vaccin relat biolog product
pdufa dupix moder sever asthma adult adolesc
pdufa xyrem cataplexi excess daytim sleepi
pdufa revefanacin lama copd
pdufa bremelanotid hypoact sexual desir disord fda adcom
schedul
american associ physicist medicin
american associ clinic chemistri
world congress cancer skin
european societi cardiolog esc
associ offici analyt chemist aoac
societi laparoendoscop surgeon minim invas surgeri week
intern network fatti acid oxid research manag
world congress pharmaci pharmaceut scienc fip
societi studi inborn metabol diseas ssiem symposium
bioprocess intern confer exhibit
advanc genom biolog technolog agbt precis meet
societi minim invas spine surgeri smiss annual forum
american societi hypertens joint w/ american heart associ aha
european migran headach trust intern congress ehmtic
american academi otolaryngolog head neck surgeri aao-hnsf
intern societi research iser biennial meet
intern associ studi pain iasp world congress pain
european academi dermatolog venereolog eadv
american societi surgeri hand assh
advanc genom biolog technolog agbt precis meet
associ vascular access annual scientif meet
heart failur societi america hfsa annual scientif meet
deadlin lpnt solicit altern acquisit propos
go live az
model recent updat pleas contact leerink repres
wish review
biopharma preview gener pain women anti-infect
hcit distribut preview pocket opportun
medic suppli devic individu co preview cardio large-cap
 takeaway immuno-oncolog panel
 takeaway nash panel
biopharma lp hic takeaway ibd panel
 takeaway migrain panel
biopharma lp hic reimburs panel oncolog gene therapi target limit
 rova-t present show anoth rout failur experiment oncolog
adap -- flash manag convers highlight data pipelin progress
adap studi advanc cell dose posit safeti data pt
-- flash present highlight opportun colorect cancer
celg updat strengthen profil remark respons durabl
celg profil continu present outperform
 tazemetostat mesothelioma data opportun combin outperform
 success pamrevlumab lapc may depend endpoint paradigm shift
imdz -- flash event highlight imdz approach strategi outperform
 event highlight investig view forward ii data outperform
-- flash highlight encourag data biomark strategi gastric
-- flash updat demonstr continu safeti earli efficaci
note wild ride ahead aaic data could drive
 ctad medacorp call aducanumab abeta hypothesi
biopharma biopharma catalyst tracker import catalyst remain second half
 takeaway annual day
 biotech portfolio concentr explain multipl compress
 first apprais tax offer small benefit
 vertex alexion top pick
-- flash takeaway leerink day outperform
 eas data confirm durabl gocovri superior vs gener
 day preview late stage program turn launch mani
 takeaway annual day
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
-- flash takeaway leerink day outperform
 growth deal capac target market
biopharma praluent show mortal benefit lower take aim highest risk group
mdco -- flash inclisiran lesson fourier/odyssey may better
novob dc highlight nvo management roundtabl discuss boston market
medic devic ada dash make splash highlight recent
medic devic leerink healthcar confer panel devic penetr set
medic devic leerink leadership seri outset drive shift dialysi self-car
novob dc highlight nvo management roundtabl boston market perform
medic devic leerink healthcar confer panel devic penetr set
medic suppli devic initi takeaway sage robot continu gain
medic devic survey support market share re-gain assumpt
medic devices-cardiolog hr takeaway cabana unlik chang af practic
biopharma price right payer fail get drug class come
 stabil sell-sid price trend medic posit ug op outperform
hcit distribut fda take step improv competit distributor near trough
 acthar survey suggest faster eros payer pressur competitor entri
qure updat model higher price assumpt po pt
 price commerci updat fda approv burosumab/crysvita
 respit price yet friendli hill fda could
biopharma trump-azar puls call drug price blueprint limit current hh
 hemophilia price adjust reflect efficaci luxturna paradigm pt
 outlook move higher price clariti suggest possibl upsid pt
hcit distribut blueprint thorough pbm like abl manag rebat
hcit distribut outlin possibl drug price polici draconian
fear
 updat hemophilia price assumpt ad pomp program pt
biopharma futur ibd categori doubl despit
biopharma ibd inflamm market grow
brand ibd medicin grow rais est
celg dose-respons plenti evid activ otezla uc outperform
celg qed ged late stage failur throw ibd bd strategi
celg ozanimod worth rang rrm ibd result outperform
ibd kol call market face disrupt jak displac tnf
uegw highlight fierc competit ibd clear-cut winner
 patent strategi come focu mitig biosimilar risk outpfrm outperform
 news patent decis one remind method use patent
 doubl extend patent horizon tecfidera
 investor sleep path ip protect pt
adap kol address controversi ahead multipl data readout outperform
 anoth setback ido outperform ideal combo still unclear
biopharma what immuno-oncolog takeaway
biopharma summari leerink immuno-oncolog roundtabl
celg anoth bet car-t probabl probabl sensibl even
 deep dive highlight oncolog focu strategi nash market perform
 highlight kol panel lung cancer io cell
celg anoth bet car-t probabl probabl sensibl even
biopharma might deton event look like screen pot match-
 sotp support current stock price where pipelin upsid market
 sotp suggest pipelin free even stock bounc market perform
 dupi miss-inventori demand trend intact partnership flail
biopharma viii partnership acquisit biopharma new top list
ci june ci cfo boston meet insight rais pt outperform
 aet bring comprehens member
dplo mid-mkt pbm acquisit complet strateg move market perform
esrx detail esrx deal term dplo may acquisit target
 evolv provid landscap initi outperform initi
outperform
 partnership valid local jaki gut de-risk develop path pt
 increas pt takeda collabor stock weak offer oppti
manag -- flash gov lose t-twx close without condit posit
pharmaci benefit manag t-twx approv bode pend ci-esrx cvs-
deal capac
-- contact leerink repres detail access podcast
 pnh survey-soliri still grow like switch monthli sc best
athn survey highlight slow market time take deal pt market
biopharma atop derm still without ped leerink dupi derm survey
 hiv survey rapid adopt biktarvi challeng outlook
hcit distribut ambulatori survey show slowdown replac market on-going
shift vbc
 vyxeo survey suggest outpati usag grow outperform
major medacorp survey lung cancer posit azn
medic devices-cardiolog tavr survey in-lin out-year trend quarter look
ew thv link link
medic suppli devic survey suggest may wait
medic devic survey support market share re-gain assumpt
 acthar survey suggest faster eros payer pressur competitor entri
 bone pick medacorp survey suggest solid crysvita adopt esp
medic devic survey direct posit mute hope
teva rais austedo sale analysi posit medacorp physician survey
 open ablat atriclip drive near term growth mi longer term
 differenti poc signific runway impli upsid pt
 ceo call focus growth outlook potenti upsid area lrp pt
outlook alpha opportun abound healthcar share
biopharma crash cours kol call highlight busi aml landscap new agent
biopharma highlight heart failur kol discuss
